Silence Therapeutics Plc - American Depository Share (SLN) Covered Calls

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of novel molecules using RNA interference (RNAi) technology. The company leverages its proprietary mRNAi GOLD platform to create short interfering RNA (siRNA) therapies that inhibit the expression of specific genes. Its primary pipeline targets high-burden diseases in three therapeutic areas: cardiovascular disease, hematology, and rare genetic conditions.

You can sell covered calls on Silence Therapeutics Plc - American Depository Share to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for SLN (prices last updated Tue 4:16 PM ET):

Silence Therapeutics Plc - American Depository Share (SLN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
5.33 +0.29 4.80 5.48 166K - 0.7
Covered Calls For Silence Therapeutics Plc - American Depository Share (SLN)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Mar 20 5 0.00 5.48 -8.8% -128.5%
Apr 17 5 0.10 5.38 -7.1% -48.9%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Silence Therapeutics plc is a biotechnology firm specializing in the development of precision-engineered medicines designed to "silence" specific genes associated with disease. The company utilizes its proprietary mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform to create short interfering RNA (siRNA) molecules. These molecules are designed to harness the body's natural RNA interference mechanism to prevent the production of disease-causing proteins. This approach allows for highly targeted treatments that can address genetic drivers of disease which were previously considered difficult to treat with traditional small molecules or antibodies.

The company's clinical pipeline is led by Zerlasiran (formerly SLN360), which is being evaluated for its potential to reduce cardiovascular risk by lowering levels of lipoprotein(a). Another key candidate is Divesiran (formerly SLN124), an siRNA molecule developed for the treatment of hematological conditions such as polycythemia vera and iron-related disorders. Silence Therapeutics also maintains high-value strategic collaborations with global pharmaceutical leaders to co-develop siRNA therapies for cardiovascular, renal, and metabolic diseases, expanding the reach of its platform technology across a broader range of medical indications.

Competitive Landscape

The field of RNA interference and gene silencing is highly competitive, with several established players and emerging biotech firms seeking to dominate the market for genetic medicines. Silence Therapeutics competes primarily with other firms utilizing siRNA and antisense technology to target liver-expressed genes. Its most direct competitor is Alnylam Pharmaceuticals, which is the industry leader in RNAi therapeutics with multiple approved products. Other major competitors in the RNA-based medicine space include Ionis Pharmaceuticals and Arrowhead Pharmaceuticals.

In the specific area of cardiovascular disease and lipoprotein(a) reduction, the company faces competition from Amgen and Novartis, both of which are developing their own late-stage therapies. Additionally, Silence Therapeutics competes for investor interest and partnership opportunities with other specialized biotechnology firms such as CrowdStrike and Xencor, which operate in different therapeutic modalities but vie for similar healthcare-focused capital. The company’s success depends on its ability to demonstrate superior safety, efficacy, and dosing profiles for its siRNA candidates relative to these established and emerging alternatives.

Strategic Outlook and Innovation

The strategic focus for Silence Therapeutics is the rapid advancement of its wholly owned clinical programs toward late-stage trials and eventual commercialization. The company is dedicated to expanding the capabilities of the mRNAi GOLD platform to target tissues beyond the liver, which would open new opportunities in extra-hepatic diseases. This ongoing innovation is supported by a robust intellectual property portfolio and a disciplined approach to research and development. By focusing on precision medicines with high unmet medical needs, the company aims to deliver transformative therapies that provide long-lasting benefits for patients with chronic and rare conditions.

Collaboration remains a central pillar of the company’s long-term strategy, as it seeks to leverage the commercial and clinical resources of its partners to accelerate pipeline growth. The company is also focused on optimizing its manufacturing processes to ensure the scalable and cost-effective production of its siRNA molecules. As the regulatory environment for genetic medicines continues to evolve, Silence Therapeutics prioritizes maintaining high standards of clinical data integrity and safety monitoring. The long-term vision is to establish the company as a foundational leader in the RNAi space, delivering a steady stream of innovative treatments across a diversified range of therapeutic areas.